ORIGINAL ARTICLE
PD-L1 expression in triple-negative breast cancer: a cross-sectional study in a Polish population
1
Department of Tumor Pathology and Pathomorphology, Oncology Center, Prof. Franciszek £ukaszczyk Memorial Hospital, Bydgoszcz, Poland
2
Chair of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland
3
Chair and Department of Oncologic Pathology and Prophylaxis, Greater Poland Cancer Center, Poznañ University of Medical Sciences and Department of Oncologic Pathology, Poznan, Poland
4
Department of Pathology, Maria Sk³odowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
Submission date: 2020-06-07
Final revision date: 2020-11-29
Acceptance date: 2020-12-28
Publication date: 2021-02-22
Pol J Pathol 2020;71(4):301-306
KEYWORDS
TOPICS
ABSTRACT
Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast carcinomas and represents an aggressive variant with a high mortality rate. PD-L1 is a protein that plays a pivotal role in suppressing the adaptive immune system. It has become a central target of the immunotherapy approach. Determining the PD-L1 status can identify TNBC patients who may benefit from targeted therapy. This study was performed to estimate the prevalence of PD-L1 expression among Polish TNBC patients. A total of 123 patients with TNBC were tested for PD-L1 expression using immunohistochemical studies. The PD-L1-positive tumors were found in 55 patients (45%), while PD-L1-negative tumors were found in 68 patients (55%). The PD-L1 positive tumors included 17 patients (31%) with the expression covering up to 1% of tumor area, 23 patients (42%) covering 2-5%, 8 patients (14%) covering 6-10% and 7 patients (13%) covering more than 10% of tumor area. The PD-L1 negative tumors included 17 patients (25%) with the expression covering less than 1% of tumor area and 51 patients (75%) with a complete lack of expression. There were no significant differences between the groups with different status of PD-L1 and the clinical tumor and lymph node stages as well as the patients’ age.
REFERENCES (34)
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30.
2.
Luo L, Zhang J, Tang H, et al. LncRNA SNORD3A specifically sensitizes breast cancer cells to 5-FU by sponging miR-185-5p to enhance UMPS expression. Cell Death Dis 2020; 11: 329.
3.
Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: The immunotherapy era. BMC Med 2019; 17: 1-9.
4.
Zhang M, Sun H, Zhao S, et al. Expression of PD-L1 and prognosis in breast cancer: A metaanalysis. Oncotarget 2017; 8: 31347-31354.
5.
Schmolze D, Behrendt CE, Lee PP, et al. The Prognostic Value of PD-L1 Expression in Triple-Negative Breast Cancer: A Cohort Study and Systematic Literature Review 2019; 1: 37-44.
6.
Dogukan R, Ucak R, Dogukan FM, et al. Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients. Eur J Breast Heal 2019; 15: 235-241.
7.
Mavaddat N, Rebbeck TR, Lakhani SR, et al. Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res 2010; 12: 1-12.
8.
Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer.
10.
Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 2013; 31: 3997-4013.
11.
Muenst S, Schaerli AR, Gao F, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014; 146: 15-24.
12.
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018; 359: 1350-1355.
13.
KöY Y, Dirilenoglu F, Tetikkurt ÜS, et al. Aldehyde dehydrogenase-1 positivity is associated with er negativity in patients with invasive ductal carcinoma of the breast. Pol J Pathol 2020; 71: 254-260.
14.
Tuzimek A, Fudalej MM, Sobiborowicz A, et al. Incorporating immunohistochemical markers into screening methods for BRCA1-mutated breast cancer. PolJ Pathol 2020; 71: 261-269.
16.
IL-1β, TNF-α, IL-4 and IL-10 on the process of carcinogenesisin the large bowel. Polish J Pathol 2012; 4: 221-227.
17.
Emens LA, Cruz C, Eder JP, et al. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients with Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol 2019; 5: 74-82.
18.
Vennapusa B, Baker B, Kowanetz M, et al. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab. Appl Immunohistochem Mol Morphol 2019; 27: 92-100.
19.
Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther 2015; 14: 847-856.
20.
Ilie M, Hofman V, Dietel M, et al. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch 2016; 468: 511-525.
21.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016; 375: 1823-1833.
22.
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
24.
Gil Del Alcazar CR, Huh SJ, Ekram MB, et al. Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov 2017; 7: 1098-1115.
25.
Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med 2016; 375: 1845-1855.
27.
versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017; 377: 1824-1835.
28.
Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
30.
Pehlivan FS, Sivrikoz ON, Dag F, et al. Distribution of CXCR4 and tumour-infiltrating lymphoc ytes in breast cancer subtypes; their relationship with each other, axillary lymph node involvement, and other prognostic indicators. Polish J Pathol 2018; 69: 335-341.
31.
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373: 123-135.
32.
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389: 255-265.
33.
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
